Latest From BaroFold Inc.
Last week's biggest headline deals occupied the fields of cancer and dementia, while a host of smaller deals included several targeting infectious diseases affecting developing countries, and vaccine and manufacturing technologies were much in evidence.
Nuron Biotech, a two-year old privately held US biologics and vaccines company, has brought in another licensing deal. It has licensed from Vitruvian BioMedical a gene-based amyloid 42 (Abeta42) vaccine that is in preclinical development for Alzheimer's disease. Nuron obtained an exclusive, worldwide licence for the vaccine and is responsible for the development and commercialisation.
Nuron Biotech, a two-year old privately held US biologics and vaccines company, has brought in its first licensing deal. It has signed an agreement with Mitsubishi Tanabe Pharma of Osaka, Japan, to commercialise its HibTiter vaccine (Haemophilus b conjugate vaccine [diphtheria CRM197 protein conjugate]) in Japan, both as a single entity and for combination product use.
- Large Molecule
- Synthesis Technologies, Production Processes
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- BaroFold Inc.
- Senior Management
Matthew Brewer, Pres. & CEO
Christian Allan, PhD, Dir., R&D
- Contact Info
Phone: (303) 926-0337
12635 E. Montview Blvd.
Aurora, CO 80045
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.